MHC class II-peptide complex (Carrier protein-derived) (pMHCII)

Carrier protein-derived peptides presented on MHC class II molecules constitute a pivotal immunological complex essential for the efficacy of conjugate vaccines (PubMed, 2012). This complex is formed when a B cell or other antigen-presenting cell (APC) internalizes a conjugate vaccine—comprising a target antigen, typically a bacterial polysaccharide, covalently linked to a carrier protein like CRM197 or tetanus toxoid (StatPearls, 2023). Inside the cell, the carrier protein is proteolytically processed into peptides that are subsequently loaded onto MHC class II molecules and displayed on the cell surface. Recognition of these peptide-MHC II complexes by the T-cell receptor (TCR) of cognate CD4+ T cells triggers T-cell activation and the provision of 'help' to B cells (Janeway's Immunobiology, 2017). This help, mediated by cytokines and surface molecules like CD40L, is necessary for B-cell isotype switching to IgG, affinity maturation, and the generation of long-lived memory B cells. Consequently, this target complex is the molecular bridge that converts T-cell-independent antigens into T-cell-dependent ones, enabling robust and durable immunity against pathogens such as Streptococcus pneumoniae and Haemophilus influenzae (NIH, 2021). Therapeutic strategies often focus on optimizing the carrier protein to ensure a diverse and potent array of these peptide-MHC complexes to overcome carrier-induced suppression and enhance long-term immunity (Vaxcyte, 2024).

Other names

Carrier-peptide-MHC II complexMHC II-peptide complexT-cell epitope-MHC II complexCarrier-specific pMHCIIpMHCII

Recruitment of CD4+ T-cell help via TCR recognition of the pMHCII complex, induction of B-cell isotype switching, promotion of affinity maturation, and generation of memory B cells (PubMed, 2012).